Stay updated on Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page.

Latest updates to the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe trial design has been updated to specify a pre-specified number of patients with stage IV M1c disease in each arm, and the collaborators now include Peter MacCallum Cancer Centre, Amgen, and Bristol-Myers Squibb. Additionally, the revision version has changed from v2.14.4 to v2.15.0.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.9%
Stay in the know with updates to Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page.